Filing identity and reporting period
The supplied filing is MEI Pharma, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2023, covering the three and nine months ended that date. This does not match the request metadata identifying Lite Strategy, Inc. and 2021 Q3; verify the filing before relying on this summary. Dollar amounts below are in millions unless stated otherwise.
Business context and key financial metrics
MEI Pharma is a clinical-stage cancer drug developer. Following the decision with Kyowa Kirin to discontinue zandelisib development, MEI said it was concentrating development resources on voruciclib and ME-344.
| Metric | Three months ended March 31, 2023 | Three months ended March 31, 2022 | Nine months ended March 31, 2023 | Nine months ended March 31, 2022 |
|---|---|---|---|---|
| Revenue | $5.9 | $9.7 | $47.4 | $29.3 |
| Operating expenses | $22.3 | $31.3 | $73.0 | $88.6 |
| Operating loss | $(16.4) | $(21.6) | $(25.7) | $(59.3) |
| Net loss | $(15.4) | $(8.7) | $(21.8) | $(38.4) |
| Basic and diluted loss per share | $(2.32) | $(1.31) | $(3.27) | $(6.31) basic; $(7.58) diluted |
Revenue principally reflected the Kyowa Kirin collaboration, including development-service reimbursements. Gross margin is not presented; operating margins are not a meaningful standalone measure for this clinical-stage business. Nine-month revenue included $16.6 million from revised estimates of obligations being closed and $8.6 million from non-refundable amounts for work that would not commence.
At March 31, 2023, cash and cash equivalents were $8.8 million and short-term investments were $103.2 million, totaling $112.0 million, down from $153.3 million at June 30, 2022. Current assets were $120.5 million and current liabilities $23.6 million. Stockholders’ equity was $34.4 million. The balance sheet reports no conventional borrowings; it includes $13.1 million of operating lease liabilities and $66.1 million of deferred revenue under the Kyowa Kirin arrangement.
Net cash used in operating activities was $41.2 million for the nine months, versus $33.2 million a year earlier. Investing activities provided $34.3 million, largely reflecting maturities of short-term investments; financing used $0.04 million, compared with $49.0 million provided in the prior-year period from an equity issuance.
Material changes versus prior comparable periods
- Quarterly revenue declined $3.8 million year over year as Kyowa Kirin reimbursements fell following the zandelisib discontinuation. Nine-month revenue rose $18.1 million, mainly because of the $25.2 million of deferred-revenue recognition described above, partly offset by lower reimbursements.
- Quarterly operating expenses fell $9.0 million, including lower zandelisib costs and personnel costs. Nine-month operating expenses fell $15.5 million; reduced program spending was partly offset by other research and development costs, including severance.
- Quarterly net loss increased despite a lower operating loss, in part because the prior-year quarter included a $12.8 million non-cash warrant revaluation gain. Nine-month net loss improved, but the comparison also reflects a much smaller warrant revaluation gain in 2023 than in 2022.
- Operating cash use increased year over year, including because the prior-year period included two $10 million Kyowa Kirin milestone receipts.
Outlook, management commentary, risks, and unusual items
- Management expected the $112.0 million of cash, equivalents, and short-term investments to fund operations for at least 12 months from the filing’s issuance. It also expected to seek future capital through equity, debt, licensing, or partnerships; additional financing is not assured.
- MEI and Kyowa Kirin discontinued global zandelisib development outside Japan after FDA guidance indicated a trial design supporting approval was not feasible within an acceptable investment timeframe. In May 2023, after the reporting date, Kyowa Kirin also decided to discontinue Japanese development; the parties intended to terminate their agreement and were closing ongoing studies.
- In February 2023, MEI agreed to acquire Infinity Pharmaceuticals in a stock merger. The filing described expected ownership of approximately 58% for existing MEI stockholders and 42% for Infinity stockholders, subject to assumptions and stockholder approvals; management expected a mid-2023 close. The merger was not certain to close and carried financing, dilution, execution, and termination risks.
- MEI reported workforce reductions affecting 28 employees in December 2022 and another 14 in April 2023. It incurred approximately $2.4 million of termination costs, including $1.8 million in research and development and $0.6 million in general and administrative expense.
- Voruciclib was in a Phase 1b study, including evaluation with venetoclax; MEI planned to report key interim data around calendar year-end 2023. ME-344 was planned for a Phase 1b colorectal cancer study in the second quarter of 2023, with interim data anticipated around year-end. These are forward-looking plans, not assured outcomes.
- Management concluded disclosure controls and procedures were ineffective because of a material weakness in controls over accounting for revenue recognition in license agreements. Remediation efforts were underway, but the filing gave no assurance they would succeed. Management nevertheless stated that the financial statements fairly presented the reported periods.
- On April 14, 2023, after quarter-end, MEI effected a one-for-twenty reverse stock split. The filing states historical share and per-share amounts were adjusted for the split.
Important facts for investors to verify
- Confirm the intended issuer and period: the source is MEI Pharma’s March 31, 2023 10-Q, not a Lite Strategy 2021 Q3 filing.
- Check the status and final terms/outcome of the proposed Infinity merger, including required approvals, closing, and any financing needs.
- Verify the termination of the Kyowa Kirin agreement, the treatment of deferred revenue and any remaining milestone or royalty rights, and the status of the zandelisib studies.
- Track actual cash burn and runway against management’s at-least-12-month estimate, given continuing operating losses and expected future financing needs.
- Review progress in remediating the material weakness in revenue-recognition controls and any subsequent changes in control effectiveness.
- Confirm clinical trial initiation, enrollment, safety findings, and data timing for voruciclib and ME-344; development plans and early findings are uncertain.